Biohaven Reports $173.4 Million Net Loss in Q3 2025, Decreases Operating Expenses

Biohaven Ltd. reported its financial results for the third quarter of 2025, revealing a net loss of $173.4 million, or $1.64 per share, compared to a net loss of $160.3 million, or $1.70 per share, for the same period in 2024. The company's total operating expenses decreased to $169.4 million from $178.2 million year-over-year, primarily due to a reduction in research and development (R&D) expenses, which fell to $141.2 million from $157.6 million. This decline was attributed to decreased spending on specific programs, particularly BHV-2000 and BHV-7000, although it was partially offset by increased personnel costs.

For the nine months ended September 30, 2025, Biohaven's net loss was $593.3 million, a decrease from $659.6 million in the prior year. Total operating expenses for this period also decreased to $602.6 million from $695.2 million, driven by a significant reduction in R&D expenses, which dropped to $513.1 million from $628.4 million. The decrease in R&D expenses was largely due to a one-time non-cash expense incurred in 2024 related to a milestone and royalty buyback agreement with Knopp Biosciences, which reduced future milestone payments.

In terms of strategic developments, Biohaven entered into a Note Purchase Agreement in April 2025, securing $250 million in gross proceeds from the sale of senior secured notes. This agreement allows for additional purchases of up to $150 million, contingent upon FDA approval of its product, troriluzole. The company also reported a significant increase in cash and cash equivalents, which rose to $184.8 million as of September 30, 2025, compared to $99.1 million at the end of 2024. However, marketable securities decreased to $75.4 million from $386.9 million during the same period.

Operationally, Biohaven is focusing on key therapeutic areas, including immunology, neuroscience, and oncology, with ongoing clinical trials for its product candidates. The company has initiated a strategic reprioritization of its clinical development programs, concentrating resources on three key areas. As of September 30, 2025, Biohaven's employee headcount was not disclosed, but the company indicated that it expects to continue hiring to support its growth strategy.

Looking ahead, Biohaven anticipates that its existing cash, cash equivalents, and marketable securities will be sufficient to fund its operations for at least the next year. The company plans to finance its operations through public or private equity financings, debt financings, or other capital sources, as it continues to pursue the development and commercialization of its product candidates.